Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia

Hematology

Volumn 15, Issue 2, 2010, Pages 74-80

  Xu, Bing ^a   Song, Xiaoyan ^a   Yip, Nga Chi ^b   Xiao, Pingnan ^a   Zhang, Yanyan ^a   Wang, Weiguang ^b   Zhou, Shuyun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Acute lymphoblastic leukemia; Mdr1; Multiplex fluorescence real time quantitative polymerase chain reaction; Prognosis; Wtl

Indexed keywords

BCR ABL PROTEIN; BICARBONATE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MESNA; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE; WT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COHORT STUDIES; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, WILMS TUMOR; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; WT1 PROTEINS; YOUNG ADULT;

EID: 77952177670     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347009937     Document Type: Article

References (34)

1. Annino L, Vegna ML, Camera A et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863-871.
2. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2006; 133-141.
3. Thomas X, Boiron JM, Huguet F et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086. (Pubitemid 41185176)
4. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
5. Marie JP, Huet S, Faussat AM et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086-1094.
6. Norgaard JM, Hokland P. Biology of multiple drug resistance in acute leukemia. Int J Hematol 2000; 72: 290-297.
7. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247: 521-534.
8. Knutsen T, Mickley LA, Ried T et al. Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drugselected cell lines and patients with drug refractory ALL. Genes Chromosomes Cancer 1998; 23: 44-54.
9. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
10. Wuchter C, Leonid K, Ruppert V et al. Clinical significance of Pglycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711-721.
11. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
12. Menssen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol 2002; 76: 103-109.
13. Sugiyama H. Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med 2002; 68: 223-237.
14. McCoy C, McGee SB, Cornwell MM. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ 1999; 10: 377-386.
15. Nagura E, Kimura K, Yamada K et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1994; 33: 359-365.
16. Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-2801.
17. Kantarjian HM, O'Brien S, Smith TL et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
18. Thomas DA, Cortes J, Giles F et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 2003; 102: 880a.
19. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 1997; 11: 1067-1072.
20. Tafuri A, Gregorj C, Petrucci MT et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002; 100: 974-981.
21. Jamroziak K, Mlynarski W, Balcerczak E et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314-321.
22. Galimberti S, Guerrini F, Carulli G et al. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004; 72: 45-51.
23. Miglino M, Varaldo R, Colombo N et al. Monitoring molecular response by BCR-ABL, JH and WT-1 in Phz all treated with imatinib containing regimen: preliminary report of two cases. J Exp Clin Cancer Res 2006; 25: 321-324.
24. Boublikova L, Kalinova M, Ryan J et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254-263.
25. Shareef MM, Brown B, Shajahan S et al. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kB and NF-Y activation in oral carcinoma cells. Mol Cancer Res 2008; 6: 89-98.
26. Bentires-Alj M, Barbu V, FilletMet al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 2003; 22: 90-97.
27. Chen Y, Williams BR. The role of NF-κB in the regulation of the expression of wilms tumor suppressor gene WT1. Gene Expr 2000; 9: 103-114.
28. Shtil AA, Azare J. Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol 2005; 246: 1-29.
29. Dehbi M, Hiscott J, Pelletier J. Activation of the WT1 Wilms' tumor suppressor gene by NF-κB. Oncogene 1998; 16: 2033-2039. (Pubitemid 28211678)
30. Kuo MT, Liu Z, Wei Y et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene 2002; 21: 1945-1954.
31. Lei HY, Zhao XL. Clinical significance of NF-κB continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 253-257.
32. Bellavia D, Campese AF, Alesse E et al. Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice. Embo J 2000; 19: 3337-3348.
33. Kirchner D, Duyster J, Ottmann O et al. Mechanisms of BCRABL-mediated NF-κB/REL activation. Exp Hematol 2003; 31: 504-511.
34. Vilimas T, Mascarenhas J, Palomero T et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.